Coherus Oncology to present CHS-114 data at SITC Annual Meeting.

viernes, 3 de octubre de 2025, 9:10 am ET1 min de lectura
CHRS--

Coherus Oncology will present a poster on CHS-114, an anti-CCR8 cytolytic monoclonal antibody, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer. The presentation will highlight the drug's selective intratumoral Treg depletion and favorable immune remodeling in advanced solid tumors. CHS-114 will also be featured in an upcoming webinar series, discussing its therapeutic target C-C chemokine receptor 8 and its role in immunosuppression.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios